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Abstract
Background: Prostatic abscesses are an uncommon disease usually caused by enterobacteria. They mostly occur in
immunodeficient patients. It is thus extremely rare to have a Staphylococcal prostatic abscess in a young
immunocompetent patient.
Case presentation: A 20-year-old patient was treated with ofloxacin for a suspicion of prostatitis. An ultrasonography
was performed because of persisting symptoms and showed acute urinary retention and prostatic abscesses. So the
empirical antibiotic therapy was modified with ceftriaxone/amikacin. The disease worsened to severe sepsis and
the patient was admitted in ICU. CT-scan and MRI confirmed three abscesses with perirectal infiltration and the
bacteriological samples (abscesses and blood cultures) were positive to methicillin-susceptible Staphylococcus
aureus producing Panton-Valentine leukocidine. The treatment was changed with fosfomycin/ofloxacin which
resulted in a general improvement and the regression of the abscesses.
Conclusion: Staphyloccocus aureus producing Panton-Valentine leukocidin are most commonly responsible for
skin and soft tissue infections. To this day, no other case of prostatic abscess due to this strain but susceptible to
methicillin has been described.
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Background
Prostatic abscesses have become uncommon and their
incidence has dropped since the introduction of antibi-
otics [1]. They are mostly due to enterobacteria, espe-
cially Escherichia coli. Sometimes Staphylococcus aureus
is involved [2] and most of the cases are due to
methicillin-resistant strains in patients with immunodefi-
ciency risk factors. These patients generally present with
chronic or subacute infections which rarely progress into
severe sepsis or septic shock. Some Staphylococcus aureus
strains can produce Panton-Valentine leukocidin (PVL),
this toxin being a virulence factor. We present here a
case of prostatic abscesses due to methicillin-susceptible
Staphylococcus aureus (MSSA) producing PVL in an im-
munocompetent patient.
Case presentation
A 20-year-old patient was admitted in the hospital be-
cause of dysuria and burning during micturition. His
medical history was unremarkable except for allergic
asthma and recurrent furuncles for a year and a half
with a negative HIV serology. Urine culture performed
1 day after symptoms appearance, showed a leukocyturia
without bacteriuria so it did not require any treatment.
Two days later, as the symptoms persisted, laboratory
tests disclosed an inflammatory syndrome including a
hyperleukocytosis (25,060 white blood cells/mm3) with a
majority of neutrophilic leukocytes, a thrombocytosis
and an increased level of C-Reactive protein (CRP) at
109 mg/L. Bladder ultrasound revealed a full bladder
which resulted in the insertion of a suprapubic catheter
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and the initiation of oral ofloxacin. The patient was dis-
charged home but presented again two days later with
abdominal and pelvic pain. New laboratory tests showed
persisting inflammatory syndrome and coagulation dis-
orders (PT at 48%). The antibiotic therapy was replaced
by ceftriaxone and amikacin. The prostate ultrasound re-
vealed two abscesses and a transrectal needle aspiration
collected 15 ml of purulent fluid with Gram positive
cocci at gram stain.
Six days later, condition worsened moving to severe
sepsis with hyperthermia, chills and hypotension. The la-
boratory tests showed a worsening of the inflammatory
syndrome (hyperleukocytosis = 43,000 white blood cells/
mm3) and of the coagulation disorders (PT at 31%) and
a hyperlactatemia at 2.90 mmol/l. Persistent perirectal
abscesses were evidenced on the pelvic magnetic reson-
ance imaging (MRI) (Figure 1). Ciprofloxacin was then
added and the patient was transferred in the intensive
care unit (ICU).
At admission, the patient was hemodynamically unstable
with a blood pressure at 98/52 mmHg requiring fluid
resuscitation. The abdomen was painful. A CT-scan evi-
denced a clear prostatic hypertrophy with several abscesses
(20 × 15 × 33 mm; 64 × 21 × 26 mm and 38 × 10 × 30 mm),
a perianal infiltration and retroperitoneal, lateral-aortic
and presacral enlarged nodes (Figure 2). Microbiological
samples from prostatic abscesses and blood cultures were
positive for MSSA producing PVL. Antimicrobial suscepti-
bility tests showed that the strain was multisusceptible
except for penicillin G, tetracycline and trimethoprim-
sulfamethoxazole. Due to the atypical clinical presentation
including multiple abscesses, we investigated by PCR
the presence of genes encoding PVL [3] that was positive.
Molecular characterization, performed by the French
National Reference Centre for Staphylococci, using DNA
microarray (Alere StaphyType DNA microarray; Alere
Technologies GmbH, Jena, Germany), highlighted that the
strain has an agr allele type 4, and was assigned to clonal
complex CC121 [4] (MLST ST 121). Data confirmed that
the strain harboured PVL genes but also genes encoding
enterotoxins B, K and Q and the egc cluster. Treatment
with fosfomycin and ofloxacin was started at admission
(D0) without need for surgery.
Apyrexia was obtained within 48 hours and the in-
flammatory syndrome improved. An echocardiography
ruled out endocarditis. The antibiotic therapy lasted six
weeks and was changed at D16 for oral rifampicin and
ofloxacin. On the same day, control MRI showed a de-
cline of the perirectal infiltration and a disappearance of
the collection in the left side of the prostate (Figure 3).
The suprapubic catheter was retrieved at D10 and pa-
tient’s micturition was normal again.
Evaluation for an oropharyngeal and nasal Staphylococcus
aureus carriage realised by swab on day 17 was negative.
Discussion and conclusions
Prostatic abscesses have become rare since the onset of
antibiotics and are found in 0.5 to 2.5% of patients with
a prostate inflammation [1]. They mostly occur in pa-
tients with local risk factors (urine retention, indwelling
urethral catheter, chronic prostatitis…) or immunodefi-
ciency risk factors [5].
The gold-standard for prostatic abscesses diagnostic is
still transrectal ultrasonography [5,6]. It allows a needle
aspiration which is used to confirm the diagnostic and
Figure 1 Pelvic MRI at D0. Pelvic MRI at D0 showing multiple
intra-prostatic abscesses: the biggest ones are situated in the right lobe.
Figure 2 Pelvic CT-scan. Pelvic CT-scan showing prostatic hypertrophy
and intra-prostatic abscesses: 20 × 15 × 33mm and 64 × 21 × 26mm in
the right lobe and 38 × 10 × 30mm in the left lobe.
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identify the microorganism involved [7]. CT-scan and
MRI are useful to assess extension around the prostate
or to look for remote focuses [8].
The most common etiologic agent is Escherichia coli
but Staphylococcus aureus is often associated with pros-
tatic abscesses [2]. Several cases of prostatic abscesses due
to community-acquired methicillin-resistant Staphylococ-
cus aureus (MRSA) have been reported in the literature
[9-12]. In our case, the etiologic agent was MSSA produ-
cing PVL. Prevalence of Staphylococcus aureus producing
PVL seems to have increased for several years: in 1995,
Prevost et al. study reported 5% of strains in Western Eur-
ope [13] whereas in 2012, 36% of strains producing PVL
were reported in the United-States [14]. This statement is
particularly true for the USA. In Europe, it is unclear
whether the prevalence has truly increased or if it is due
to increased ascertainement. Moreover, in Europe, there is
clonal heterogeneity [15]. In the USA, there is a strong as-
sociation between strains producing PVL and MRSA [14].
In Europe, Australia and Africa, there is a high proportion
of MSSA producing PVL [16-19]. In our case the strain
producing PVL was susceptible to methicillin. MSSA
strains producing PVL are often from the clonal complex
CC121, ST 121 [20,21].
The PVL is a synergohymenotropic toxin that acts
through the association of two components F and S. It
destroys cells by creating pores in the membrane [22]
and is responsible for leukocyte and macrophage destruc-
tion and tissue necrosis. Its role in the pathogenesis and
the spreading of infections is still unclear [23]. Strains pro-
ducing PVL are usually linked with skin infections such as
furuncles and abscesses, with necrotising pneumonia [23]
and with bone and joint infections [24] that mostly occur
in healthy children and young adults.
PVL may contribute to the infection severity and be a
virulence factor. This could explain that our patient
presented with severe sepsis. Studies conducted in ani-
mals showed that PVL led to the persistence of infec-
tion and made its local extension easier [25]. Other
studies highlighted a higher frequency of hemoptysis,
general signs (tachycardia, low blood pressure, polyp-
nea and cyanosis) and deaths in pneumonia caused by
Staphylococcus aureus producing PVL, which illustrates
the virulence of the toxin [22]. In 2013, Shallcross et al.
showed in a meta-analysis that infections were most
likely to recur and surgery performed more often in
skin and soft tissue infections caused by strains produ-
cing PVL [26]. Of note, the patient had a history of re-
petitive furuncles for a year and a half which could be
linked with recurrence. To our knowledge, this is the
first case of prostatic abscess due to Staphylococcus
aureus producing PVL with the toxin possibly respon-
sible for the severe sepsis.
Prostatic abscesses treatment usually includes an anti-
biotic therapy adapted to the microorganism and drain-
age of the abscess. Ultrasound-guided transrectal needle
aspiration must be preferred to surgical drainage or
transurethral prostatic resection as the needle path is
shorter and the tolerance rate higher [27]. The antibiotic
treatment aims at eradicating Staphylococcus aureus but
it must also decrease the toxin effects. In 2008, a study
evidenced the ability of linezolid, clindamycin and rifam-
picin to inhibit PVL production [28].
Prostatic abscesses must be searched for in all patients
presenting with prostatitis symptoms associated with ab-
dominal pain. A Staphylococcus aureus origin must be
suspected if the disease worsens and develops to severe
sepsis despite an adapted antibiotic therapy, especially in
a young subject. Moreover, if this pathogen producing
PVL is discovered, an antibiotic therapy including toxin
inhibition must be started.
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Figure 3 Pelvic MRI at D16. Control pelvic MRI at D16 showing
regression of the abscesses in the left lobe and persistence in the
right lobe.
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